Monopar Therapeutics (MNPR) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $69.27, -3.52% vs the prior close of $71.80.
- Volume 142.40K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
MNPR slides 3.5% to $69.27, a 3-month low. Closed at $69.27, -3.52% vs the prior close of $71.80. Day range $68.81–$71.01, opened at $71.01.
MNPR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — MNPR slides 3.5% to $69.27, a 3-month low
- Closed at $69.27, -3.52% vs the prior close of $71.80. Day range $68.81–$71.01, opened at $71.01.
- Volume was 142.40K shares, 0.8x its 50-day average of 174.40K.
- Price is -30.6% vs its 50-day average ($99.86) and -9.9% vs its 200-day average ($76.88).
- 52-week range $50.07–$124.82; today's close sits at 26% of that range, 44.5% below the 52-week high.
Oct 15, 2026 — MNPR dips 1.8% to $71.80, a 3-month low
- Closed at $71.80, -1.78% vs the prior close of $73.10. Day range $70.05–$73.28, opened at $73.20.
- Volume was 140.90K shares, 0.8x its 50-day average of 175.24K.
- Price is -28.8% vs its 50-day average ($100.88) and -6.6% vs its 200-day average ($76.85).
- 52-week range $50.07–$124.82; today's close sits at 29% of that range, 42.5% below the 52-week high.
Oct 14, 2026 — MNPR rises 1.4% to $73.10
- Closed at $73.10, +1.42% vs the prior close of $72.08. Day range $70.51–$74.01, opened at $70.74.
- Volume was 129.60K shares, 0.7x its 50-day average of 176.95K.
- Price is -28.2% vs its 50-day average ($101.83) and -4.8% vs its 200-day average ($76.82).
- 52-week range $50.07–$124.82; today's close sits at 31% of that range, 41.4% below the 52-week high.
Oct 13, 2026 — MNPR slides 6.5% to $72.08, a 3-month low, 3 down days in a row
- Closed at $72.08, -6.45% vs the prior close of $77.05. Day range $71.66–$76.92, opened at $76.16.
- Volume was 249.90K shares, 1.4x its 50-day average of 181.73K.
- Price is -29.8% vs its 50-day average ($102.74) and -6.1% vs its 200-day average ($76.80).
- 52-week range $50.07–$124.82; today's close sits at 29% of that range, 42.3% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — MNPR dips 2.4% to $77.05, a 3-month low
- Closed at $77.05, -2.42% vs the prior close of $78.96. Day range $75.05–$79.59, opened at $79.30.
- Volume was 128.50K shares, 0.7x its 50-day average of 187.79K.
- Price is -25.6% vs its 50-day average ($103.53) and +0.3% vs its 200-day average ($76.80).
- 52-week range $50.07–$124.82; today's close sits at 36% of that range, 38.3% below the 52-week high.
Oct 9, 2026 — MNPR slides 6.0% to $78.96
- Closed at $78.96, -5.98% vs the prior close of $83.98. Day range $78.80–$84.04, opened at $83.47.
- Volume was 135.80K shares, 0.7x its 50-day average of 191.61K.
- Price is -24.2% vs its 50-day average ($104.16) and +2.9% vs its 200-day average ($76.76).
- 52-week range $50.07–$124.82; today's close sits at 39% of that range, 36.7% below the 52-week high.
Oct 8, 2026 — MNPR ends flat (+0.2%) to $83.98, 4 up days in a row
- Closed at $83.98, +0.24% vs the prior close of $83.78. Day range $81.26–$85.49, opened at $82.48.
- Volume was 185.50K shares, 1.0x its 50-day average of 195.05K.
- Price is -19.9% vs its 50-day average ($104.87) and +9.5% vs its 200-day average ($76.72).
- 52-week range $50.07–$124.82; today's close sits at 45% of that range, 32.7% below the 52-week high.
- That makes 4 straight gains.
Oct 7, 2026 — MNPR jumps 5.3% to $83.78, 3 up days in a row
- Closed at $83.78, +5.29% vs the prior close of $79.57. Day range $77.98–$85.03, opened at $78.28.
- Volume was 107.00K shares, 0.5x its 50-day average of 203.49K — lighter than usual.
- Price is -20.5% vs its 50-day average ($105.34) and +9.3% vs its 200-day average ($76.65).
- 52-week range $50.07–$124.82; today's close sits at 45% of that range, 32.9% below the 52-week high.
- That makes 3 straight gains.
Oct 6, 2026 — MNPR rises 1.6% to $79.57
- Closed at $79.57, +1.63% vs the prior close of $78.29. Day range $75.32–$82.66, opened at $78.04.
- Volume was 302.20K shares, 1.5x its 50-day average of 204.24K.
- Price is -24.8% vs its 50-day average ($105.85) and +3.9% vs its 200-day average ($76.56).
- 52-week range $50.07–$124.82; today's close sits at 39% of that range, 36.3% below the 52-week high.
Oct 5, 2026 — MNPR rises 0.4% to $78.29
- Closed at $78.29, +0.41% vs the prior close of $77.97. Day range $76.24–$79.59, opened at $78.72.
- Volume was 128.30K shares, 0.6x its 50-day average of 206.27K.
- Price is -26.5% vs its 50-day average ($106.46) and +2.3% vs its 200-day average ($76.50).
- 52-week range $50.07–$124.82; today's close sits at 38% of that range, 37.3% below the 52-week high.
Oct 2, 2026 — MNPR ends flat (+0.0%) to $77.97, 8 down days in a row
- Closed at $77.97, +0.00% vs the prior close of $77.97. Day range $77.03–$80.00, opened at $78.36.
- Volume was 107.60K shares, 0.5x its 50-day average of 210.08K — lighter than usual.
- Price is -27.2% vs its 50-day average ($107.09) and +2.0% vs its 200-day average ($76.46).
- 52-week range $50.07–$124.82; today's close sits at 37% of that range, 37.5% below the 52-week high.
- That makes 8 straight losses.
MNPR latest news & SEC filings
Every SEC filing by or about MNPR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Starr Christopher M converted options/RSUs into 8,400 shares at $0.01 (≈$42) on Oct 1, 2026; now holds 13,573
- Starr Christopher M sold 4,631 shares at $78.09 (≈$361.63K) on Oct 1, 2026; now holds 8,942
- Starr Christopher M sold 2,970 shares at $78.82 (≈$234.10K) on Oct 1, 2026; now holds 5,972
- Starr Christopher M sold 799 shares at $79.67 (≈$63.66K) on Oct 1, 2026; now holds 5,173
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cittadine Andrew converted options/RSUs into 4,384 shares on Sep 30, 2026; now holds 59,998
- Cittadine Andrew had withheld for taxes 1,944 shares at $79.67 (≈$154.88K) on Sep 30, 2026; now holds 58,054
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Robinson Chandler converted options/RSUs into 9,801 shares on Sep 30, 2026; now holds 109,068
- Robinson Chandler had withheld for taxes 4,344 shares at $79.67 (≈$346.09K) on Sep 30, 2026; now holds 104,724
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Vu Quan Anh converted options/RSUs into 614 shares on Sep 30, 2026; now holds 2,835
- Vu Quan Anh had withheld for taxes 180 shares at $79.67 (≈$14.34K) on Sep 30, 2026; now holds 2,655
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Robinson Chandler converted options/RSUs into 14,056 shares at $30.00 (≈$421.68K) on Sep 24, 2026; now holds 113,323
- Robinson Chandler converted options/RSUs into 15,000 shares at $14.00 (≈$210.00K) on Sep 24, 2026; now holds 128,323
- Robinson Chandler sold 10,450 shares at $87.15 (≈$910.72K) on Sep 24, 2026; now holds 117,873
- Robinson Chandler sold 9,638 shares at $87.96 (≈$847.76K) on Sep 24, 2026; now holds 108,235
- Robinson Chandler sold 8,368 shares at $88.97 (≈$744.50K) on Sep 24, 2026; now holds 99,867
- Robinson Chandler sold 600 shares at $89.79 (≈$53.87K) on Sep 24, 2026; now holds 99,267
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$5.31M (prior year -$2.45M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.62 (prior year -$0.35) (loss widened vs Jun 30, 2025)
Jul 22, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Jul 22, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Jul 22, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Jul 22, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Jul 22, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Things to know before you trade MNPR
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 27, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.59% (largest 7.5%).
- Liquidity: about 160.93K shares (≈$11.15M) trade per day on average.
- 52-week position: $69.27 vs a range of $50.07–$124.82 (26% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Chandler Robinson sold 600 shares on Sep 24, 2026.
- Latest filings: 8-K Aug 12, 2026; 10-Q Aug 12, 2026; 8-K Jul 22, 2026.
- Share count: 6.71M shares outstanding (Jul 31, 2026), +8.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
MNPR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 71.01 | 71.01 | 68.81 | 69.27 | 142.40K |
| Oct 15, 2026 | 73.20 | 73.28 | 70.05 | 71.80 | 140.90K |
| Oct 14, 2026 | 70.74 | 74.01 | 70.51 | 73.10 | 129.60K |
| Oct 13, 2026 | 76.16 | 76.92 | 71.66 | 72.08 | 249.90K |
| Oct 12, 2026 | 79.30 | 79.59 | 75.05 | 77.05 | 128.50K |
| Oct 9, 2026 | 83.47 | 84.04 | 78.80 | 78.96 | 135.80K |
| Oct 8, 2026 | 82.48 | 85.49 | 81.26 | 83.98 | 185.50K |
| Oct 7, 2026 | 78.28 | 85.03 | 77.98 | 83.78 | 107.00K |
| Oct 6, 2026 | 78.04 | 82.66 | 75.32 | 79.57 | 302.20K |
| Oct 5, 2026 | 78.72 | 79.59 | 76.24 | 78.29 | 128.30K |
| Oct 2, 2026 | 78.36 | 80.00 | 77.03 | 77.97 | 107.60K |
| Oct 1, 2026 | 79.64 | 80.33 | 77.59 | 77.97 | 130.80K |
| Sep 30, 2026 | 80.00 | 82.35 | 79.33 | 79.67 | 226.30K |
| Sep 29, 2026 | 82.77 | 83.04 | 79.38 | 80.00 | 162.40K |
| Sep 28, 2026 | 85.24 | 86.69 | 82.92 | 83.72 | 268.20K |
| Sep 25, 2026 | 89.58 | 90.00 | 85.06 | 85.24 | 105.80K |
| Sep 24, 2026 | 88.03 | 90.05 | 86.54 | 88.84 | 252.90K |
| Sep 23, 2026 | 96.78 | 96.78 | 87.59 | 89.38 | 89.30K |
| Sep 22, 2026 | 96.60 | 97.37 | 94.00 | 96.63 | 136.00K |
| Sep 21, 2026 | 97.92 | 98.19 | 94.95 | 95.72 | 89.20K |
About Monopar Therapeutics
Monopar Therapeutics (MNPR) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WILMETTE, IL. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1645469.
MNPR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Raymond Anderson | Director | Aug 28, 2026 |
| Arthur J Klausner | Director | Dec 19, 2025 |
| Chandler Robinson | Chief Executive Officer | Sep 28, 2026 |
| Christopher M Starr | Director | Dec 8, 2025 |
| Nicole Sweeny | Director | Jun 30, 2026 |
| Lavina Talukdar | Director | Dec 8, 2025 |
| Kim R Tsuchimoto | Director | Aug 28, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Andrew Cittadine | Chief Operating Officer | Jul 2, 2026 |
| Chandler Robinson | Chief Executive Officer | Sep 28, 2026 |
| Susan Rodriguez | CCSO | Mar 4, 2026 |
| Quan Anh Vu | Chief Financial Officer | Jul 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 24, 2026 | Chandler Robinson | Sale | 600 | $89.79 |
| Sep 24, 2026 | Chandler Robinson | Sale | 8,368 | $88.97 |
| Sep 24, 2026 | Chandler Robinson | Sale | 9,638 | $87.96 |
| Sep 24, 2026 | Chandler Robinson | Sale | 10,450 | $87.15 |
| Sep 24, 2026 | Chandler Robinson | Sale | 600 | $89.79 |
| Sep 24, 2026 | Chandler Robinson | Sale | 8,368 | $88.97 |
| Sep 24, 2026 | Chandler Robinson | Sale | 9,638 | $87.96 |
| Sep 24, 2026 | Chandler Robinson | Sale | 10,450 | $87.15 |
| Sep 24, 2026 | Chandler Robinson | Sale | 600 | $89.79 |
| Sep 24, 2026 | Chandler Robinson | Sale | 8,368 | $88.97 |
| Sep 24, 2026 | Chandler Robinson | Sale | 9,638 | $87.96 |
| Sep 24, 2026 | Chandler Robinson | Sale | 10,450 | $87.15 |
| Sep 24, 2026 | Chandler Robinson | Sale | 600 | $89.79 |
| Sep 24, 2026 | Chandler Robinson | Sale | 8,368 | $88.97 |
| Sep 24, 2026 | Chandler Robinson | Sale | 9,638 | $87.96 |
MNPR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-13.72M | -1.85 | $-12.20M |
| Dec 31, 2024 | $0 | $-15.59M | -4.11 | $-6.40M |
| Dec 31, 2023 | $0 | $-8.40M | -3.04 | $-7.86M |
| Dec 31, 2022 | — | $-10.52M | -0.83 | $-7.23M |
| Dec 31, 2021 | — | $-9.10M | — | $-7.32M |
Latest balance sheet: total assets $134.98M, total liabilities $4.12M, cash $52.76M (as of Jun 30, 2026).
MNPR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $114.90 |
| May 14, 2026 | 8-K Item 2.02 (results) | $60.99 |
| Mar 27, 2026 | 8-K Item 2.02 (results) | $54.10 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $87.01 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $35.90 |
| May 13, 2025 | 8-K Item 2.02 (results) | $33.82 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $36.41 |
| Nov 8, 2024 | 8-K Item 2.02 (results) | $16.88 |
| Aug 9, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 28, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on MNPR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.